SCHEMBL1339138

SCHEMBL1339138

Cn1c(=O)c(-c2ccc(Cl)cc2Cl)cc2c3cc(-c4nnc(N)s4)ccc3n(C)c21

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 6/20 0.48
▸ ALDH1A1 P00352 4/20 0.48
▸ GAA P10253 3/20 0.48
▸ RAB9A P51151 3/20 0.48
▸ MGAM O43451 2/20 0.48
▸ SI P14410 2/20 0.48
▸ MGAM2 Q2M2H8 2/20 0.48
▸ MAPT P10636 2/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ NOTUM Q6P988 1/20 0.41
▸ PIM1 P11309 8/20 0.39
▸ PIM3 Q86V86 8/20 0.39
▸ PIM2 Q9P1W9 7/20 0.39
▸ CNR1 P21554 2/20 0.38
▸ CNR2 P34972 2/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ HSD11B1 P28845 2/20 0.37
▸ HPGD P15428 2/20 0.35
▸ HSD17B10 Q99714 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1338076 0.84 CNR1 (0.40) KDM4EALDH1A1GAARAB9ACNR1
SCHEMBL1339432 0.83 CNR1 (0.40) KDM4EALDH1A1GAARAB9ACNR1
SCHEMBL1338617 0.82 KDR (0.39) KDM4EALDH1A1GAACNR1CNR2
SCHEMBL4761794 0.81 KDM4E (0.35) KDM4EALDH1A1GAACNR1CNR2
SCHEMBL1339227 0.81 GABRA1 (0.41) KDM4EALDH1A1GAARAB9ACNR1
SCHEMBL1336852 0.80 SHMT1 (0.38) KDM4EALDH1A1GAARAB9AL3MBTL1
SCHEMBL3568345 0.80 CNR1 (0.39) KDM4EALDH1A1GAACNR1CNR2
SCHEMBL1338051 0.80 CNR1 (0.39) KDM4EALDH1A1GAAMAPTCNR1
SCHEMBL1336976 0.79 TRIM24 (0.41) KDM4EALDH1A1GAARAB9AMAPT
SCHEMBL1339427 0.79 CNR1 (0.38) KDM4EALDH1A1GAARAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063061-B2 6-(2-amino-1,3-thiazol-4-yl)-3-(2,4-dichlorophenyl)-1-methyl-1,9-dihydro-2H-pyrido[2,3-b]indol-2-one; affinity for GABAA-receptor-associated omega modulatory sites SANOFI-AVENTIS (FR) 2011-11-22 — — US disclosed
EP-1940840-B1 6-HETEROARYLPYRIDOINDOLONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF SANOFI AVENTIS (FR) 2010-07-21 — — EP disclosed
US-20080262020-A1 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof SANOFI-AVENTIS (FR) 2008-10-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080262020-A1 6-Heteroarylpyridoindolone Derivatives, Their Preparation and Therapeutic Use Thereof CYP11B2, CYP11B1, CYP2D6 KDM4E 1908/4885ALDH1A1 283/4885GAA 1532/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback